Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks
Details : Nexletol(bempedoic acid) is an adenosine triphosphate-citrate lyase inhibitor indicated as an adjunct to diet and statin therapy for heart attack, hypercholesterolaemia & cardiovascular diseases.
Brand Name : Nexletol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2024
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Daiichi Sankyo
Deal Size : $1,255.0 million
Deal Type : Collaboration
Esperion and Daiichi Sankyo Amend $125M Collaboration, Resolve Litigation
Details : The collaboration combines Esperion Therapeutics’ NILEMDO (bempedoic acid), an ACL inhibitor, with Daiichi Sankyo’s commercial capabilities for cardiovascular medicines.
Brand Name : Nilemdo
Molecule Type : Small molecule
Upfront Cash : $30.0 million
January 03, 2024
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Daiichi Sankyo
Deal Size : $1,255.0 million
Deal Type : Collaboration
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nexletol (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...
Brand Name : Nexletol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2022
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL
Details : NEXLETOL (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...
Brand Name : Nexletol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2022
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : H.C. Wainwright & Co.
Deal Size : $225.0 million
Deal Type : Public Offering
Esperion Announces Pricing of $225 Million Public Offering
Details : Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes.
Brand Name : Nexletol
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 02, 2021
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : H.C. Wainwright & Co.
Deal Size : $225.0 million
Deal Type : Public Offering
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
Details : Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of ...
Brand Name : Nexlizet
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2021
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Daiichi Sankyo
Deal Size : $1,130.0 million
Deal Type : Partnership
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
Details : The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s commercial capabilities, as well as synergies with their existing portfolio of cardiovascular medicines.
Brand Name : Nexlizet
Molecule Type : Small molecule
Upfront Cash : $30.0 million
April 26, 2021
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Daiichi Sankyo
Deal Size : $1,130.0 million
Deal Type : Partnership
Lead Product(s) : Bempedoic Acid,Ezetimibe,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.
Brand Name : Nexletol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 17, 2021
Lead Product(s) : Bempedoic Acid,Ezetimibe,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Recipient : Serometrix
Deal Size : Undisclosed
Deal Type : Agreement
ESPERION Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
Details : ESPERION has entered into a definitive agreement with Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Serometrix developed the oral PCSK9 inhibitor program with its proprietary technology to discover drugs for difficult protein...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Recipient : Serometrix
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.
Brand Name : Nexletol
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 13, 2020
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?